Basit öğe kaydını göster

Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis

dc.contributor.authorYazici, Y.
dc.contributor.authorYazici, H.
dc.date.accessioned2021-03-06T08:56:50Z
dc.date.available2021-03-06T08:56:50Z
dc.date.issued2008
dc.identifier.citationYazici Y., Yazici H., "Tumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, cilt.26, ss.449-452, 2008
dc.identifier.issn0392-856X
dc.identifier.othervv_1032021
dc.identifier.otherav_e3609d61-add4-495e-8493-192ad5c9d0ad
dc.identifier.urihttp://hdl.handle.net/20.500.12627/149635
dc.description.abstractObjective. The relative high cost and potential side effects mandate careful scrutiny as to when tumor necrosis factor alpha (TNF) inhibitors should be used in everyday practice. We surveyed how TNF inhibitors performed in randomized controlled trials when compared to methotrexate in methotrexate naive rheumatoid arthritis patients.
dc.language.isoeng
dc.subjectİmmünoloji ve Romatoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleTumor necrosis factor alpha inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis
dc.typeMakale
dc.relation.journalCLINICAL AND EXPERIMENTAL RHEUMATOLOGY
dc.contributor.departmentCity University Of New York Brooklyn College , ,
dc.identifier.volume26
dc.identifier.issue3
dc.identifier.startpage449
dc.identifier.endpage452
dc.contributor.firstauthorID187556


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster